In this trial, canakinumab was effective in controlling and preventing flares in patients with colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, and TRAPS. (Funded by Novartis; CLUSTER ClinicalTrials.gov number, NCT02059291 .).
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.
This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.
BackgroundImmunodysregulation polyendocrinopathy enteropathy x-linked(IPEX) syndromeis a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined.ObjectiveThis analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors.MethodsClinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed.ResultsWe confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n = 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS.ConclusionsPatients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by
autosomal dominant mutations in PIK3CD (APDS1) or
PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency.
While initial cohort-descriptions summarized the spectrum of clinical and
immunological manifestations, questions about long-term disease evolution and
response to therapy remain. The prospective European Society for Immunodeficiencies
(ESID)-APDS registry aims to characterize the disease course, identify outcome
predictors, and evaluate treatment responses. So far, 77 patients have been recruited
(51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients
pinpoints the early occurrence of recurrent respiratory infections followed by
chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias.
Although most manifestations occur by age 15, adult-onset and asymptomatic courses
were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a
CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had
received at least one immunosuppressant, but 2–3 lines of immunosuppressive
therapy were not unusual before age 10. Response to rapamycin was rated by physician
visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation
showed the best response (8 complete, 11 partial, 6 no remission), while bowel
inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2
partial, 9 no remission) responded less well. Hence, non-lymphoproliferative
manifestations should be a key target for novel therapies. This report from the
ESID-APDS registry provides comprehensive baseline documentation for a growing cohort
that will be followed prospectively to establish prognostic factors and identify
patients for treatment studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.